Milestones in Medicine Over the Past 30 Years and Prof. Dr. Mustafa Özdoğan's Vision for 2050
In this article
Scientific Revolutions, the Rise of Technology, and the Future of People-Centered Healthcare
📌 Why Are These Milestones So Important?
Since 1995, technology, global epidemics, and social changes have fundamentally transformed medical practice. This process has reshaped every area, from diagnosis and treatment to health policy. This article examines the medical revolutions of the past 30 years and presents a vision for 2050.
1. A Revolution in HIV/AIDS Treatment: HAART
1996marked the introduction of the triple-combination approach known as highly active antiretroviral therapy (HAART). It transformed HIV infection from a fatal condition into a manageable, chronic disease. While first-generation regimens required 20+ pills daily and strict dosing schedules, today single-tablet combinations and even monthly/2-monthly long-acting injections are becoming widespread. HAART's impact is revolutionary not only for individual survival but also for breaking transmission at the population level .
Key data (summary):
- AIDS-related deathshave fallen from their global peak by approximately 60–70% , restoring millions of life-years.
-
U = U (Undetectable = Untransmittable): When treatment reduces the blood viral level in people with HIV to an undetectable level (<50 copies/mL), the risk of sexual transmission falls to zero.
-
Evidence: In HPTN 052, transmission decreased by 96%; in PARTNER and PARTNER 2, 0 cases were observed.
-
-
Mother-to-child transmission: Appropriate treatment during pregnancy and suitable delivery/breastfeeding protocols can reduce mother-to-child transmission to below 1% .
-
PrEP (Pre-Exposure Prophylaxis): Preventive medicines (tenofovir/emtricitabine or long-acting agents) for individuals at high risk of HIV can provide >90% protection .
-
Modern treatment regimens: INSTI-based combinations (e.g., dolutegravir, bictegravir) offer a high barrier to resistance, few side effects, and convenient use.
📈 Timeline: Milestones
| Topic | 1990s (before HAART) | Today (the INSTI era) |
|---|---|---|
| Number of medicines | Many pills daily | Single tablet or long-acting injection |
| Side effects | Frequent and substantial | Fewer and manageable |
| Viral suppression | Difficult, frequent resistance | High success (INSTIs) |
| Transmission risk | High | Viral load <50: ≈0 (U=U) |
| Life expectancy | Shortened | Near normal with early treatment |
🩺 Effects on Clinical Practice
- Test and start immediately: Rapid ART for everyone diagnosed.
- Smart selection: Resistance testing + drug-interaction checks.
- Prevention: Promote PrEP/PEP and the U=U message.
- Pregnancy management: An appropriate regimen and individualized delivery and breastfeeding plans.
Illustrative case: In 1998, CD4=120/mm³ and viral load=350,000 copies/mL. After HAART, viral load <50 at month 6, CD4 >350 at month 12. Today, sustained suppression with a single-tablet INSTI regimen; hypertension/diabetes comorbidities are managed in the usual way. Life expectancy is close to the general population's.
🧩 Ongoing Challenges
- A vaccine and a "cure" are not yet available; research continues.
- Late diagnosis and inequalities make continuity of care difficult.
- Long-term follow-up: Side effects and polypharmacy.
🚀 What Is on the Horizon?
- Monthly/2-monthly injections and new agents given every 6 months.
- Implants/subcutaneous depot systems.
- Resistance-based personalized treatment.
Intersection with oncology:
- Fewer cancers associated with immune deficiency.
- Antiretroviral–chemotherapy/immunotherapy drug interactions require attention (CYP).
- Holistic management of aging and comorbidities.
Further reading:
- HPTN 052, PARTNER/2— U=U evidence
- NEJM/Lancet—development of HAART & INSTIs
- UNAIDS/WHO—epidemiology and the care cascade
2. The Rise of Biotechnology and Genetic Testing
Approval of trastuzumab for HER2-positive breast cancer in 1998 and imatinib for CML/GIST in 2001 launched the era of "smart drugs" in oncology. By directly targeting specific genetic abnormalities, these medicines showed for the first time that some cancers could be controlled over the long term and, in some patients, become a chronic disease . Biomarker-based treatment consequently evolved rapidly toward a clinical standard.
Completion of the Human Genome Project in 2003accelerated this transformation and made the transition of molecular medicine into practice lasting. From the 2010s, next-generation sequencing (NGS) panels transformed diagnosis across oncology, cardiogenetics, infections, and rare diseases. Publicly, Angelina Jolie's BRCA1 carrier status in 2013 and preventive surgery dramatically increased genetic awareness; individual risk management, screening, and preventive surgical options entered mainstream discussion.
💡 Clinical Revolution: Medicines Bringing Cancer Closer to a Chronic Disease
Imatinib – CML
- In the 1990s, average survival was ~3–5 years .
- After imatinib, 5-year survival ≥89%; in complete responders, ≥95% at 8 years.
- 10-year survival ≈82–83%, close to the general population.
Trastuzumab – HER2+ Breast Cancer
- In metastatic disease, median survival increased from 20.3 months to 25.1 months .
- In adjuvant use, recurrence risk decreased by 9.5%, while the risk of death at 3 years decreased by 3%.
- 5-year disease-free survival 75% → 84%, 7-year overall survival 90% → 94%.
Note: These rates are based on typical survival data from major clinical studies published in journals such as NEJM and Lancet.
Concrete Effects in Clinical Practice:
- Oncology: Tumor panels (50–500+ genes) identify targets such as EGFR, ALK, ROS1, BRAF, HER2, MET, NTRK, RET to select targeted therapies . MSI-H/dMMR and TMB are biomarkers used to identify candidates for immunotherapy .
- Pharmacogenomics: TPMT/NUDT15 (thiopurines), DPYD (5-FU/capecitabine), CYP2D6 (tamoxifen/antidepressants) testing personalizes dose and medicine selection , reducing toxicity.
- Prenatal screening: NIPT analyzes fetal DNA from maternal blood; trisomy 21/18/13 and other aneuploidies can be detected with high sensitivity and specificity.
- Rare diseases: Exome/whole-genome sequencing shortens time to diagnosis and reduces the "diagnostic odyssey"; in suitable patients, gene therapies can be considered.
🕒 Timeline: From the Genome to Clinical Practice
| Test/Biomarker | Clinical Decision | Concrete Effect |
|---|---|---|
| HER2 amplification (breast) | HER2-targeted treatments such as trastuzumab ± pertuzumab/TDxD | Improved response and survival; changed adjuvant & metastatic standards |
| BCR–ABL fusion (CML) | Tyrosine kinase inhibitors (e.g., imatinib, second/third generation) | Deep molecular response and long-term disease control |
| BRCA1/2 (breast/ovarian) | Screening frequency, risk-reducing surgery, PARP inhibitor | Lifelong risk management, improved PFS |
| EGFR/ALK/ROS1 (LC) | Selection of a tyrosine kinase inhibitor | Marked improvements in response rate and PFS |
| MSI-H/dMMR, TMB | Immunotherapy eligibility | Tumor-agnostic approvals, durable responses |
| TPMT/NUDT15 | Thiopurine dose/alternative | Risk of severe myelosuppression ↓ |
| DPYD | 5-FU/capecitabine dose modification | Risk of fatal toxicity ↓ |
Illustrative case (breast cancer):
Age 40, triple-negative metastatic breast cancer. BRCA1 A pathogenic variant is identified. A PARP inhibitor is started after standard chemotherapy; an objective response is achieved and PFS is substantially prolonged. Genetic counseling and screening are planned for first-degree relatives.
⚖️ Ethics, Regulation, and Infrastructure
- Data privacy, biobanks, secondary use, and consent models.
- Variant classification (pathogenic/VOUS) and reporting standards (e.g., ACMG).
- Inequalities in access: Access to testing/treatment, reimbursement policies, education.
- Integration: Structured recording of genetic results in E-Nabız/EHR systems and clinical decision support.
🚀 What Is on the Horizon?
- Liquid biopsy: ctDNA monitoring of minimal residual disease and early detection of recurrence.
- Multi-omics profiling (genome + transcriptome + proteome + metabolome): treatment selection and response prediction.
- Gene editing (CRISPR/base/prime): clinical applications from monogenic diseases to hemoglobinopathies and leukemias.
- Personalized vaccines (neoantigen mRNA/dendritic cell): adjuvant/personalized approaches in solid tumors.
4. Surgical and Legal Developments
Surgery has been redefined over the past 30 years by minimally invasive techniques, robotic systems, image-guided navigation, 3D printers, AI-assisted planning, and ERAS (Enhanced Recovery After Surgery) protocols. In parallel, the legal and regulatory framework has also changed fundamentally around telemedicine, reproductive health, data privacy, medical-device safety, and AI applications.
Key indicators (summary):
- Minimally invasive surgery (laparoscopic/robotic) can shorten the average hospital stay for many procedures by 1–3 days ; wound complications and blood loss also decrease significantly.
- ERAS protocols typically reduce postoperative complications by %20–30 and accelerate functional recovery.
- Robotic surgery offers advantages in selected indications, particularly in confined pelvic and thoracic spaces, through nerve-sparing approaches and 3D vision .
- Normothermic organ perfusion and similar technologies may improve assessment and utilization rates for donor organs .
🩺 Technological Advances in Surgery
- Minimally invasive and robotic: Laparoscopic cholecystectomy has become the standard; in robotic procedures such as radical prostatectomy, hysterectomy, and partial nephrectomy, reports describe reduced blood loss and shorter hospitalization , with early functional recovery .
- Image-guided navigation & AR/VR: Neuronavigation and fluorescence imaging (e.g., ICG) allow clearer identification of resection margins ; VR for preoperative planning and AR for intraoperative guidance.
- 3D printers and patient-specific guides: In complex orthopedic/maxillofacial reconstruction, these can reduce operating time and incision size and enable personalized implants.
- ERAS: Multimodal analgesia, early mobilization, and restricted-fluid strategies reduce ileus and complication rates, with a lower risk of readmission .
- Organ transplantation and perfusion: Ex-vivo normothermic perfusion allows the viability of marginal organs to be assessed and can reduce ischemia-reperfusion injury.
- Artificial intelligence and automation: Preoperative images enable anatomical segmentation, risk scoring, and complication prediction; surgical videos enable skills analytics and quality metrics.
🕒 Timeline: Selected Milestones
| Area | Before | After / Current | Concrete Effect |
|---|---|---|---|
| Cholecystectomy | Open surgery; large incision | Laparoscopic standard | Less pain, 1–2 days shorter hospitalization |
| Prostatectomy | Open approach | Robot-assisted | Blood loss and transfusion requirements ↓; earlier recovery of continence/erectile function (selected series) |
| Colorectal surgery | Conventional care | ERAS protocol | Complications ~%20–30 ↓; ileus and length of stay ↓ |
| Liver transplantation | Cold-ischemia assessment | Normothermic perfusion | Marginal organ acceptance and early function ↑ (experience from selected centers) |
Illustrative case A:
A patient with localized prostate cancer undergoes robotic prostatectomy, with EBL substantially reduced, early catheter removal , and negative surgical margins on pathology. Recovery of continence/erectile function at month 6.
Illustrative case B:
Complex mandibular reconstruction: preoperative 3D modeling and patient-specific plates reduce operating time and blood loss ; cosmetic/functional outcomes are favorable.
⚖️ Legal and Regulatory Changes
- Reproductive health: In the United States, after Dobbs (2022) , differences among states and issues around obstetric emergencies, medication abortion, travel, and telemedicine affected clinical workflows.
- Data privacy: GDPR (EU) and HIPAA (US) are frameworks relevant to medical images/videos and surgical data used for AI; secondary use raises questions of consent and anonymization.
- Medical devices and software: The EU MDR tightened clinical-evidence and post-market surveillance criteria; software as a medical device (SaMD) assessments expanded.
- Telemedicine and licensing: Compliance with licensing/professional-liability rules in cross-border services; for e-prescribing and remote monitoring, requirements for identity verification, log, audit apply.
- Artificial intelligence: In healthcare, regulations are being considered for high-risk AI systems to meet transparency, traceability, and data-quality requirements (e.g., EU AI legislation).
- “Right-to-Try / Expanded Access”: Defining access outside clinical trials for patients who have exhausted standard treatment options and sharing responsibilities.
The perspective from Türkiye (summary):
- Robotic/minimally invasive capacity and center experience are growing; training/accreditation and cost-effectiveness assessments are priorities.
- Telehealth and remote monitoring require guidelines and infrastructure development, including e-prescription and e-signature integration.
- Data protection (KVKK) involves anonymization and explicit consent processes for educational and AI use of clinical data/surgical videos.
🧩 Challenges and 🚀 What Is on the Horizon?
- Learning curve and cost: Sustainable training, maintenance, and consumable costs for robotic/AR systems.
- Inequality: The effects of regional/institutional differences in access to advanced technology on patient outcomes.
- AI safety: Data bias, explainability, and the chain of responsibility; designing human-based approval processes.
- Future: Autonomous assistants, haptic-feedback robotics, real-time bleeding/semi-automated suture detection; an ecosystem of personalized implants/grafts.
For further reading (source types):
- ERAS/robotic meta-analyses and guideline updates in surgical journals
- EU MDR/US FDA guidance for medical devices and software
- GDPR/KVKK/HIPAA frameworks for telehealth and data protection
- Current judicial/regulatory decisions concerning reproductive health, AI, and cross-border services
🚀 Looking Ahead: A Healthcare Vision for 2050
1. Artificial Intelligence and Digital Twins
A digital twincombines a patient's clinical information, imaging, genetics, and wearable-device data into a single personalized model. The model simulatesdifferent treatment options, predicts possible outcomes, and provides physicians with decision support . In oncology in particular, it combines tumor biology and the patient's physiology to help select the plan with the highest response and lowest toxicity .
Building blocks of a digital twin
- Data: EHR, laboratory results and vital signs, MRI/CT/PET, pathology, omics (NGS/ctDNA), wearable sensors, lifestyle/environment.
- Models: Risk scores (prognostic), causal comparisons, mechanistic PK/PD models, and tumor-growth models.
- Infrastructure: Data harmonization through FHIR/OMOP; MLOps, federated learning, and privacy-preserving computation.
- Governance: Clinical approval loops (human oversight), explainability (XAI), calibration, and drift monitoring.
🧭 End-to-End Workflow
| Area | What Is Needed? | Decision | Expected Effect |
|---|---|---|---|
| Oncology (response/toxicity) | NGS/ctDNA, pathology, CT/PET, laboratory results and vital signs | Regimen/dose selection, early changes | PFS/OS ↑, serious AEs ↓ |
| Cardiology (early warning) | Echocardiography, BNP, HRV, medication records | Diuretic/ACEi adjustment, close monitoring | Readmissions ↓ |
| Intensive care (sepsis) | Continuous vital signs + laboratory trends | Early antibiotics/fluids | Mortality/LOS ↓ |
| Endocrinology (glycemic control) | CGM, activity/meal records | Medication and behavioral adjustments | Time-in-range ↑, hypoglycemia ↓ |
| Home healthcare | IoT measurements, questionnaires | Remote intervention/visits | Emergency visits ↓ |
Illustrative example: EGFR L858R -mutant metastatic lung cancer (NSCLC).
- Simulation: 3rd-generation TKI vs TKI + local ablation. Liver burden and raised ALP predict an advantage for the combined approach.
- Early indicator: At week 6, ctDNA decrease >90% → increased likelihood of radiological response.
- Implementation: Frequent toxicity monitoring for 4 weeks; failure to meet the ctDNA threshold at week 6 triggers a treatment change.
Checklist for Safe Use
- Performance: AUROC/AUPRC + calibration (Brier, slope/intercept).
- External validation: Multicenter testing; subgroup analysis.
- Drift: Data/concept drift alerts; periodic recalibration.
- Human approval: Approval by two clinicians for high-risk recommendations.
Implementation roadmap (example)
- 0–6 months: Data inventory, FHIR/OMOP mapping, pilot cohort.
- 6–12 months: Retrospective validation + "shadow mode."
- 12–24 months: Limited use within the MDT; outcome measurement and training.
- 24–48 months: Multicenter expansion; integration with home healthcare.
Measure and Improve (KPIs)
- Diagnosis-to-treatment time (TAT)
- G≥3 adverse events and accuracy of dose modifications
- Readmission / emergency visit rate
- PFS/OS gains
- User trust (MDT acceptance, alert accuracy)
Ethical and Regulatory Principles
- Fairness: Representation in training data; bias testing and correction.
- Transparency: XAI explanations, decision logs, version traceability.
- Privacy: Federated learning, differential privacy, explicit consent.
- Compliance: SaMD criteria, safety reporting, and post-implementation monitoring.
2. Synthetic Biology and 3D Bioprinters
Synthetic biologyreprograms cells through engineering to perform desired functions. Gene circuits add "if–then" logic to cells, enabling them to sense, decide, and respond. 3D bioprinters print cells and biomaterials layer by layer, using bioink to create tissue-like structures. The combination of these fields is preparing one of the greatest advances in regenerative medicine, oncology, and microbial therapiesover the next 10–20 years.
Core components
- DBTL cycle (Design–Build–Test–Learn): Design → Build the DNA/scaffold → Test → Learn and improve.
- Bioink: GelMA, alginate, fibrin, collagen and similar hydrogels + living cells + biomolecules.
- Printing methods: Extrusion (most common), inkjet (precise), laser-assisted (high resolution).
- Cell sources: Primary cells, iPSC derivatives, mesenchymal stem cells; a universal donor goal.
- Support modules: Vascularization uses sacrificial inks, growth-factor-releasing capsules, and electrical/mechanical stimulation.
🧭 From Design to the Clinic
🧱 Tissue Complexity: From Simple to Advanced
Note: Printing full-size solid organs (liver/kidney) remains at the research stage; the greatest barriers are vascularization and long-term function.
| Area | Approach | Concrete Goal | Expected Effect |
|---|---|---|---|
| Regenerative Medicine | 3D-printed skin/cartilage/bone, growth-factor-releasing structures | Repair of burns and bone defects | Number of operations ↓, compatibility ↑, healing ↑ |
| Oncology | Logic-gated CAR/TCR cells; tumor-on-a-chip | Specificity ↑, cytokine storm risk ↓; personalized drug selection | Response rate ↑, improved toxicity management |
| Microbial Therapies | Production of metabolites/enzymes using engineered probiotics | IBD, metabolic disorders, infection control | Targeted effects; systemic adverse effects ↓ |
| Drug Discovery | Rapid screening with organoids/organ-on-a-chip | Candidate selection and toxicity prediction | Early elimination → cost and time ↓ |
Quality and Safety—Practical Checkpoints
- Cell viability after printing generally targets >%70 ; functional markers (ALP, collagen).
- Sterility & endotoxin testing; no contamination → release.
- Mechanical suitability: Elastic modulus/compression ranges for cartilage/bone.
- Immunogenicity/tumorigenicity: Long-term monitoring of iPSC derivatives; insertional mutagenesis risk.
Example A (orthopedics):
For traumatic tibial segment loss, a vascularization-supporting 3D-printed bioceramic-hydrogel graft; faster bone integration and less need for a second operation.
Example B (oncology laboratory):
A patient-specific tumor organoid + immune co-culture provides a personalized drug panel in 2 weeks; strong preliminary evidence for a targeted/immunotherapy combination at the decision stage.
⚖️ Ethics, Regulation, and Biosafety
- ATMP scope; GMP manufacturing, traceability, pharmacovigilance.
- Dual-use risk: engineered microbes require kill-switch and encapsulation.
- Equitable access: Scalable production (biofoundries) and open protocols.
- Data privacy: Consent and secure sharing of cellular/omics data.
Quick Wins for Türkiye
- University–hospital–industry collaboration to establish core bioprinting laboratories and a shared GMP pilot facility.
- ATMP-focused clinical research units and a reimbursement framework.
- At burn/orthopedic centers, early-adoption pilots; organoid platforms in oncology.
- A standard QC panel (viability, mechanics, sterility) and training programs.
🚀 What Is on the Horizon?
- 4D bioprinting: Smart biomaterials that change shape/function over time.
- Advanced vascular networks: Dense capillarization through microfabrication and sacrificial inks.
- AI-assisted design: Multi-objective optimization for cell density, porosity, and flow.
- Universal donor cell banks: HLA-edited, broadly compatible sources.
3. Home Healthcare: Homes Are Becoming Mini-Hospitals
Healthcare's focus is shifting from large hospitals toward the patient's home . With advanced sensors, AI-assisted analysis, telehealth, and mobile care teams, homes effectively function as "mini-hospitals" . This model offers a solution to population aging, the rising burden of chronic disease, and staff shortages that is scalable and accessible .
Building Blocks of the Home Healthcare Ecosystem
- IoT devices: Smartwatches/ECG patches, blood-pressure, glucose, and SpO₂ sensors; data flow into clinical dashboards in real time.
- Telehealth: Video consultations, prescriptions, remote specialist consultation; AI triage for decision support.
- Home mini-laboratory: Rapid blood/urine test cartridges, home sample collection, and integration with mobile laboratories.
- Nursing & care: Wound care, injections/IV treatment, rehabilitation; early detection of complications.
- Smart-home infrastructure: Fall and movement sensors, medication reminders/automatic dispensers, a safe home layout.
Lessons From Programs (Examples)
- United States – Hospital-at-Home: In appropriately selected patients, complication risk is approximately 20% lower, with substantial reductions in readmissions and costs reported.
- Japan: National home-monitoring programs aim to improve access and continuity for millions of older people.
- Europe: Telemonitoring for COPD/heart failure has reportedly reduced emergency visits and readmissions .
| Advantage | Explanation | Measured/Frequently Reported Effect |
|---|---|---|
| Lower hospital burden | Home monitoring instead of admission for suitable cases | 15–25% of intensive-care/ward capacity freed (during peak periods) |
| Chronic disease control | Continuous measurement + remote medication/lifestyle management | HbA1c reduction of ~0.8–1.2%; in hypertension, crisis-related visits ↓ |
| Fewer readmissions | Preventing exacerbations through early warning and home visits | 10–30% reduction in 30-day readmissions (depending on disease/center) |
| Patient experience | Care in familiar surroundings, family support | Satisfaction ≥90%; improved treatment adherence |
Priority Steps in Türkiye
- SGK reimbursement packages for home nursing, teleconsultations, and remote monitoring.
- Smart-home integration: A standard set of fall sensors, medication dispensers, and emergency call systems.
- Mobile laboratory/sample-collection networks expanded in major cities.
- Nurses and caregivers need home-care certification and triage protocols.
🚀 A Home Healthcare Vision for 2030–2050
- In every home, an integrated biosensor station and a personal AI health assistant.
- Drone delivery of medicines/medical supplies and cold-chain monitoring.
- Home-based ventilators and monitoring for "intermediate care."
- In major cities, hospital-at-home networks with logistics, data, and quality-management standards.
4. Preventive Medicine and Early Warning Systems
Preventive medicineaims to detect and prevent disease before symptoms begin. Wearable technologies, AI algorithms, and continuous monitoring systems now allow potential risks to be recognized weeks or even months in advance . This paradigm shift will reduce the burden on healthcare systems and improve individuals' quality of life.
Core Tools of Preventive Medicine:
- Wearable devices: Smartwatches, ECG patches, and glucose sensors can detect irregular heart rhythms with an average of 95% accuracy .
- Biomarker screening: Early cancer detection using ctDNA and proteomic tests significantly improves 5-year survival in colorectal, lung, and breast cancer.
- AI-assisted risk scoring: Automatic risk analysis using EHR data; in sepsis warning systems, mortality decreases by 20%.
- Smart-home monitoring: Fall sensors and respiratory monitoring help older people live independently for longer.
Example Scenarios:
- Cardiology: Early atrial fibrillation detection can reduce stroke risk by up to 60%.
- Oncology: ctDNA testing can detect tumor recurrence 6–12 months before radiological imaging.
- Diabetes: Continuous glucose monitors and AI algorithms reduce hypoglycemia risk by 70%.
The Process From Risk to Prevention:
- Data collection: Sensors, laboratory results, genetic screening, lifestyle information.
- AI analysis: Big-data algorithms generate individual risk scores.
- Warning systems: Patients and physicians are notified immediately if thresholds are exceeded.
- Preventive intervention: Medication, lifestyle changes, or rapid medical intervention.
The perspective from Türkiye:
- In primary healthcare centers, preventive screening programs should be digitized.
- For high-risk groups, sensor-assisted home follow-up and nursing visits.
- Cancer screening programs (breast, cervical, colorectal) can improve access through AI-assisted appointment management .
🚀 Looking Ahead:
- Home-based biosensor networks: Devices monitoring health parameters in every room.
- Personal AI health assistant: Detects unusual changes in daily activities and sends alerts.
- Genome-based preventive medicine: Polygenic risk scores and targeted dietary/lifestyle advice.
- Global early warning systems: International data networks predicting outbreaks and environmental risks.
5. Advances in Aging Science and Senolytics
Aging science has moved rapidly from laboratory research to clinical trials over the past decade. Aging is now viewed not merely as an inevitable biological process but as a biological mechanism that can be targeted. Clearing cells known as senescent cells , which have lost their capacity to divide and release inflammatory signals, plays a critical role in strategies to slow aging.
Core Concepts:
- Senescent cells: Cells that stop dividing because of DNA damage or stress and secrete pro-inflammatory cytokines.
- SASP (Senescence-Associated Secretory Phenotype): Contributes to chronic inflammation, tissue damage, and the aging phenotype.
- Senolytic medicines: Small molecules that selectively target and eliminate senescent cells (e.g., the Dasatinib + Quercetin combination).
- Senomorphics: Medicines that suppress the harmful secretory profile of senescent cells, controlling them without eliminating them.
Examples From Clinical Trials:
- Dasatinib + Quercetin (D+Q): In 2019, improved age-related kidney dysfunction in mice and improved lung capacity in people with idiopathic pulmonary fibrosis (IPF).
- Fisetin: An antioxidant flavonoid; extended lifespan and reduced chronic disease burden in older mice. Clinical trials are ongoing.
- UBX1325: A senolytic agent; demonstrated vascular improvement in diabetic macular edema.
🧬 Mechanisms of Aging
| Area | Approach | Expected Effect |
|---|---|---|
| Cardiology | Reducing vascular stiffness and cardiac fibrosis with senolytics | Heart failure risk ↓, vascular elasticity ↑ |
| Oncology | Clearing senescent cells that accumulate after chemotherapy | Secondary cancer risk ↓, quality of life ↑ |
| Eye Health | Treating diabetic macular edema with agents such as UBX1325 | Visual acuity ↑, frequency of intraocular injections ↓ |
Opportunities in Türkiye:
- In older populations, screening programs and R&D support for biomarker research.
- Partnerships with pharmaceutical and biotechnology companies for senolytic drug development .
- At hospitals, more multidisciplinary centers focused on geriatric oncology .
🚀 Looking Ahead:
- Combined aging targets: Integrating senolytics, telomerase activators, and metabolic modulators.
- Personalized biological age: Individual aging profiles using epigenetic clocks and proteomic panels.
- Longevity clinics: Centers combining genetic screening, regenerative treatment, and lifestyle coaching.
🌟 Conclusion: A Future That Retains the Human Touch
Technology and a people-centered approach will advance together in medicine. As AI and biotechnology support physicians, caregivers and nurses will become even more important. The greatest challenge of the next 30 years will be turning this technological power into equitable, humane healthcare for everyone .
| Area | Before the Pandemic | After the Pandemic |
|---|---|---|
| Telehealth | Rarely used, pilot projects | Routine in 60%+ of clinics, consultations from home |
| Vaccine development | 10–15 years | Approval in 10 months with mRNA |
| Supply chain | Globalized, vulnerable | Localization, stockpiling strategies |
| Masks/PPE | Generally restricted to hospitals |
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.